Plasma Fractionation Market Insights, Share, Growth Drivers and Forecast by 2024

New York, United States, 2019-Jul-19 — /EPR Network/ —

Plasma fractionation is a method used for segregating plasma into its different components. Proteins present in plasma are mainly used for therapeutic purposes in the treatment of various diseases. Factors primarily responsible for the growth of the global plasma fractionation market are increased prevalence of rare diseases, surge in geriatric population, and growing use of immunoglobulins in different therapeutic domains.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market/report-sample

On the basis of product type, the plasma fractionation market is categorized into immunoglobulins, coagulation factors, albumins, and protein inhibitors, wherein immunoglobulins hold the largest revenue share in the market. This is attributed to the rising prevalence of primary immunodeficiency disease (PIDD). For instance, treatment of PIDD is mainly dependent upon regular infusion therapy where immunoglobulins are involved in the treatment procedure. The market for albumins is expected to observe the fastest growth, owing to rapid use of the products in various drug formulations, especially for drugs used in treatment of acute liver diseases.

Based on application, the plasma fractionation market is classified into neurology, immunology, hematology, pulmonology, and rheumatology. Among all the application areas, plasma fractionation products are majorly used in neurology, due to high prevalence of neurological disorders. Moreover, successful results have been obtained by the use of intravenous immunoglobulins for the treatment of neurological diseases.

Browse full report at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market

Key market players are focusing on the development of highly improved and technologically advanced products, to increase their share in the global plasma fractionation market. For instance, in December 2018, Novo Nordisk attained U.S. Food and Drug Administration (USFDA) approval for Novoeight, a drug manufactured by plasma fractionation method. This drug is used to treat patients suffering from hemophilia A.

Some of the other players operating in the plasma fractionation industry are CSL Behring, Japan Blood Products Organization, Green Cross Corp., Bio Product Laboratory Ltd., Octapharma AG, Kedrion S.p.A., and Grifols International S.A.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Facebook

Blog: https://healthcarenews.home.blog/